Teva Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?
TEVA PHARMS has three hundred and twenty approved drugs.
There are three US patents protecting TEVA PHARMS drugs. There are forty-three tentative approvals on TEVA PHARMS drugs.
There are nineteen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and forty-three supplementary protection certificates in eighteen countries.
Summary for Teva Pharms
| International Patents: | 19 |
| US Patents: | 3 |
| Tradenames: | 264 |
| Ingredients: | 259 |
| NDAs: | 320 |
Drugs and US Patents for Teva Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | OLMESARTAN MEDOXOMIL | olmesartan medoxomil | TABLET;ORAL | 091079-003 | Apr 24, 2017 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Teva Pharms | FLUOCINONIDE | fluocinonide | SOLUTION;TOPICAL | 072522-001 | Sep 28, 1990 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Teva Pharms | CEFUROXIME SODIUM | cefuroxime sodium | INJECTABLE;INJECTION | 064191-001 | Apr 16, 1998 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Teva Pharms | CETIRIZINE HYDROCHLORIDE | cetirizine hydrochloride | SOLUTION;ORAL | 077279-001 | May 27, 2008 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Teva Pharms Usa | ATAZANAVIR SULFATE | atazanavir sulfate | CAPSULE;ORAL | 091673-004 | Apr 22, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Teva Pharms | HALOPERIDOL | haloperidol lactate | CONCENTRATE;ORAL | 071617-001 | Dec 1, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Teva Pharms Usa | BLEOMYCIN SULFATE | bleomycin sulfate | INJECTABLE;INJECTION | 065033-002 | Jun 27, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,342,476 | ⤷ Subscribe |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,342,476 | ⤷ Subscribe |
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 9,375,410 | ⤷ Subscribe |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 8,367,605 | ⤷ Subscribe |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 5,981,589 | ⤷ Subscribe |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,939,539 | ⤷ Subscribe |
| Teva Pharms Intl | SYNRIBO | omacetaxine mepesuccinate | POWDER;SUBCUTANEOUS | 203585-001 | Oct 26, 2012 | 7,842,687 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Premature patent expirations for TEVA PHARMS
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Subscribe | ⤷ Subscribe |
International Patents for Teva Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009102408 | ⤷ Subscribe |
| Denmark | 2177223 | ⤷ Subscribe |
| Canada | 2459822 | ⤷ Subscribe |
| Japan | 2005508896 | ⤷ Subscribe |
| Spain | 2334774 | ⤷ Subscribe |
| Japan | 4794816 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2019071111 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | 122016000109 | Germany | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, Z.B. EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN. EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 2962690 | CR 2019 00033 | Denmark | ⤷ Subscribe | PRODUCT NAME: APREMILAST ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/981 20150116 |
| 1532149 | 132013902118390 | Italy | ⤷ Subscribe | PRODUCT NAME: LINAGLIPTIN + METFORMINA CLORIDRATO(JENTADUETO); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/780/001 A EU/1/12/780/027, 20120720 |
| 0584952 | 99C0004 | Belgium | ⤷ Subscribe | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306 |
| 0236940 | SPC/GB97/013 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: LETROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: FR 341 474-2 19960724; FR 341 475-9 19960724; UK PL00001/0224 19961118 |
| 0114027 | 96C0022 | Belgium | ⤷ Subscribe | PRODUCT NAME: FLUVASTATINE SODIQUE; NAT. REGISTRATION NO/DATE: 151 IS 207 F 4 19960409; FIRST REGISTRATION: GB 0101/0360 19930823 |
| 1304992 | PA2013025 | Lithuania | ⤷ Subscribe | PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
